T cells

[Cell Reports] By performing both whole-genome CRISPR and metabolic inhibitor screens, researchers identified that nicotinamide phosphoribosyltransferase (NAMPT) was required for T cell activation.

[iScience] Utilising an in vitro migration assay, regulatory T cells from patients with psoriatic arthritis treated with conventional therapy paradoxically boosted CCR6+ effector T cell migration towards CCL20.

[Cancer Immunology Research] Scientists modeled tumor-specific MEK inhibition (MEKi) through CRISPR/Cas-mediated genome editing of tumor cells and pharmacologic MEKi with cobimetinib in a RAS-driven model of colorectal cancer.

[Blood] This phase I-II study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). BV and Nivo with staggered or concurrent dosing were active and well tolerated when used as first salvage therapy in patients with r/r cHL.

[Cell Reports] Scientists used genetic engineering to create human PSCs in which the majority of the polymorphic human leukocyte antigens, the main drivers of allogeneic rejection, were deleted.

[Cell] Scientists identified that colorectal cancer manifested with altered ILC3s that were characterized by reduced frequencies, increased plasticity, and an imbalance with T cells.